Furthermore, understanding how these rates of change compare to other commonly used measures of atherogenic burden may help inform the clinical utility of apoB measurement in young adults, as more stable measures may serve as more reliable markers of an individual patient’s expected future burden of atherogenic lipoproteins, and they may perform better as long-term ASCVD risk markers in young adults. This evidence concerns the gene APOB and atherosclerosis.